Antengene Biologics Limited
Clinical trials sponsored by Antengene Biologics Limited, explained in plain language.
Biopharmaceutical company developing oncology and hematology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
Disease control Not yet recruitingThis phase 1 trial is testing an experimental drug called ATG-201 in adults with systemic lupus erythematosus, systemic sclerosis, or Sjögren's disease. ATG-201 is designed to bind to specific proteins on immune cells, potentially quieting the overactive immune response that driv…
Phase 1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Sep 21, 2026 16:00 UTC
-
Can a targeted drug outperform chemotherapy for stomach cancer?
Disease control Not yet recruitingThis trial tests whether an experimental drug called ATG-022 can slow the growth of advanced stomach or gastroesophageal junction cancer better than standard chemotherapy. The study enrolls adults whose tumors show a specific marker called CLDN18.2 and who have already tried at l…
Phase 3 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC